Gilead Sciences

Open: 78.39 Close: 77.44 Change: -0.95

Are you looking for information about Gilead Sciences Stock? We programmed an AI to summarize it for you.

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, company, HIV, biopharmaceutical, develop, hepatitis, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. The company is in the Health Care sector and Biotechnology industry.

Today's News

U.S. markets close in 4 hours 6 minutes S&P 500 4,144.44 +7.21 (+0.21%) Dow 30 32,648.55 -135.75 (-0.41%) Nasdaq 12,734.94 +139.34 (+1.11%) Crude Oil 84.06 +0.85 (1.02) Gold 1,9921 , -,)Consumer fixes priovohibitedRuss trades Phillip collectorsamedhan dolphin Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. Gileads has been recognized as the top philanthropic funder of HIV-related programs for the second year. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company is in the Health Care sector and Biotechnology industry. Gilead Sciences stock Snapshot 57.00 Bid 100.00 Ask 100.05. Average price target is 56.00. Median: 80.39 - 112.00 - The average price target includes all analyst analysis. Gilead Sciences is currently working to offer long-acting oral and injectable options of lenacapavir as a single agent for prevention of HIV. The next wave of innovation in HIV includes long-action options that are aiming to help address the needs and preferences of the diverse range of individuals and communities affected by the epidemic.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, company, HIV, biopharmaceutical, develop, hepatitis, and the most common words in the summary are: gilead, science, stock, market, job, inc, best, . One of the sentences in the summary was: The company is in the Health Care sector and Biotechnology industry.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #market #job #inc #best.